Tag Archives: Novartis

JPM 2025 Day 2: LLY, AZN, SNY, NVS, BAY, AKRO, SRRK, SDZ, MRK, TDOC, VTRS; Dario Partners for GLP-1RA Solution Expansion

On the second day of JPM 2025, FENIX has provided coverage of presentations by major CVRM companies, including Lilly, AstraZeneca, Sanofi, Novartis, Bayer, Akero, Scholar Rock, Sandoz, Merck, Teladoc, and Viatris. Of note, JPM experienced webcast issues during the 9:45 AM PT time slot. Separately, one CVRM-related news item has been observed: Dario partnered with MediOrbis for GLP-1RA solution expansion (view press release).

This content is for Read Less members only.

Already a member? Log in here

Amgen MariTide Ph2 Topline Results; Alnylam sNDA Accepted for Vutrisiran with PRV; Novartis Investor Event

Three cardiometabolic-related news items have been observed: Amgen announced topline 52-week data from its Ph2 MariTide obesity study (view press release); Alnylam announced FDA accepted the vutrisiran sNDA for the treatment of ATTR-CM with a PDUFA date on March 25, 2025 (view press release); and Novartis recently hosted a “Meet the Management” investor day (view press release; CEO presentation; breakout slides). Below, FENIX provides highlights and insights for the respective news items, including thoughts on Amgen’s placement in the obesity treatment paradigm.

This content is for Read Less members only.

Already a member? Log in here

Lexicon Faces Uphill Battle in Sota T1DM Adcom; Pfizer and Novartis Q3 ’24 Earnings; Sanofi Invests in Another Obesity Asset; MariTide T2DM Trial; Sagimet to Advance Denifanstat MASH Development

A series of cardiometabolic-related news items have been observed from FDA/Lexicon, Pfizer, Novartis, Sanofi, Amgen, and Sagimet Biosciences. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Dexcom Hosts Stelo Webinar; Libre 3 CGM Recall; Novartis Positive Ph3 Leqvio Trial Results; President Biden Releases Statement on AOM Prices

A series of cardiometabolic-related news items have been observed from Dexcom, Abbott, Novartis, and the Biden Administration. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Lilly Opens New R&D Center; Tandem t:connect iOS App Recall Update; Lexicon to Refocus Business Including Salesforce Layoffs; Novartis Loses Generic Entresto Case; Galectin Q2 ’24 Earnings

A series of cardiometabolic-related news items have been observed from Lilly, Tandem, Lexicon, Novartis, and Galectin. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Tandem, Lexicon, and Vertex Q2 ’24 Earnings; Novartis Sues FDA Over Entresto Generic

A series of cardiometabolic-related news items have been observed from Tandem, Lexicon, Vertex, and Novartis. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Abbott and Novartis Q2 ’24 Earnings

Two cardiometabolic-related news items have been observed: Abbott (press release; infographic) and Novartis (press release; slides) hosted their respective Q2 ’24 earnings calls. Below, FENIX provides highlights and insights about the respective items.

This content is for Read Less members only.

Already a member? Log in here

Tandem Mobi Integrated with Dexcom G7; Ro Launches GLP-1 Supply Tracker; Novartis Initiates Ph4 Inclisiran vs. BA H2H Study; AZ Ph1 Oral PCSK9i Results; Catalent Stockholders Approve Acquisition by Novo

A series of cardiometabolic-related news items have been observed from Tandem, Ro, Novartis, AstraZeneca, and Catalent/Novo. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novartis Q1 ’24 Earnings; Vertex Partners with TreeFrog for T1DM Manufacturing

Two cardiometabolic-related news items have been observed: Novartis hosted its Q1 ’24 earnings call (press release; slides); and Vertex announced an exclusive licensing agreement with TreeFrog Therapeutics for TreeFrog’s proprietary cell manufacturing technology (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Nanexa’s Ph1 QM Liraglutide Study Delayed; SAB Completes Dosing in Ph1 T1DM Trial; Novartis’s Iptacopan IgAN sNDA Receives Priority Review; Ypsomed Partners with Ten23 for Patch Injector; JNJ Q1 ’24 Earnings

A series of cardiometabolic-related news items have been observed from Nanexa, SAB, Novartis, Ypsomed, and J&J. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here